Business Inquiry
Global:
Email:marketing@medicilon.com
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
• New drug development
In particular, patient screening and predictive biomarker studies in clinical trials of tumor immune-targeted drugs show that PDX efficacy evaluation results and clinical similarity reached 87% (CDX only 5%).
• Personalized Medicine:
PDX model can be used to conduct pharmacodynamic (PD) evaluation experiments for tumor patients, providing clinical drug references for personalized treatment.
• Molecular Marker development (Biomarker)
Drug reactions -- Molecular biological mechanisms